In this free webinar, hear about lessons learned and important considerations for novel retina therapy programs. Attendees will get insights from experts about the latest published research and regulatory agency reviews of clinical designs. The featured speakers will discuss patient sample considerations and how working with certain outside-USA locations can improve timelines and be better suited to find the best-fit patients for studies. Attendees will get an overview of various endpoints within the retinal space, with an understanding of how condition-dependent endpoints can provide the best chance of program success.
TORONTO, Nov. 27, 2023 /PRNewswire-PRWeb/ -- In this groundbreaking webinar, discover the latest in retina therapy programs and clinical research to enhance success in ophthalmic trials with insights from industry experts. With over 250 individual therapies in development to address these challenging-to-treat conditions including inherited retina diseases, diabetic retinopathy and macular degeneration, the innovation within this space is likely unsurpassed by any other. Excitingly, many of these include novel mechanisms of action or gene therapies that show potential for different therapeutic impacts from current therapies on the market, such as treating conditions where there are no therapies with approved indications or targeting earlier-stage disease interventions.
As companies explore new therapies to address these disease states, new strategies are needed for clinical designs that measure therapeutic impact appropriate for the target patients and stage of disease. Join Ora's Vice President of Posterior Segment Keith Lane, and Retina Specialist and Ora Head of LATAM Operations Dr. Joao (John) Trein, as they share lessons learned and important considerations for novel retina therapy programs.
Using insights from the latest published research and regulatory agency reviews of clinical designs, these speakers will overview various endpoints within the retinal space, with an understanding of how condition-dependent endpoints can provide the best chance of program success. The team will also review patient sample considerations and how working with certain outside-USA locations can improve timelines and be better suited to finding the best-fit patients for studies. This talk will cover study considerations across a plethora of intervention approaches from traditional pharmaceuticals to gene therapy to novel neuroprotection interventions.
Join this webinar to gain insights into retina therapy programs in clinical research from industry experts to maximize success in the challenging field of ophthalmic clinical trials.
Join Keith Lane, Ora Vice President Posterior Segment; and Dr. Joao (John) Trein, Ora Head of LATAM Operations, Retina Specialist, for the live webinar on Monday, December 11, 2023, at 11 am EST (4 pm GMT/UK).
For more information, or to register for this event, visit Navigating Industry Needs for Retina Therapy Clinical Research Success.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com
SOURCE Xtalks
